Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: Alastair Smith, Avacta Group CEO gives an Operational Update


Hikma Share Price (HIK)



Share Price Information for Hikma (HIK)


Share Price: 1,873.50Bid: 1,868.00Ask: 1,870.00Change: -9.00 (-0.48%)Faller - Hikma
Spread: 2.00Spread as %: 0.11%Open: 1,874.50High: 1,891.00Low: 1,850.00Yesterday’s Close: 1,882.50

Hikma Pharmaceuticals Plc Ord Shs 10P

Hikma is listed in the FTSE 250, FTSE All-Share, FTSE 350, FTSE 350 Low Yield
Hikma is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
1873.50
Share Price SpacerBid
1868.00
Share Price SpacerAsk
1870.00
Share Price SpacerChange
-0.48%-9.00
Share Price SpacerVolume
536,742
Share Price SpacerOpen
1,874.50
Share Price SpacerHigh
1,891.00
Share Price SpacerLow
1,850.00
Share Price SpacerClose
1,882.50
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 241.42m £4,523.02m 1,000

52 Week High 2,033.00 52 Week High Date 5-SEP-2018
52 Week Low 814.20 52 Week Low Date 1-MAR-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
2,551 190,131 308,043 -7.167 -261.39 25.45 1.36


London South East Users info for Hikma




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

20-Sep-18
17:41:48
1,862.551
11,419
Sell* 
1,868.00
1,870.00
212.68k
Trade Type:
Ordinary

20-Sep-18
17:33:07
1,863.32
2,770
Sell* 
1,868.00
1,870.00
51.61k
Trade Type:
Ordinary

20-Sep-18
17:24:01
1,872.81
63
Buy* 
1,868.00
1,870.00
1,180
Trade Type:
Ordinary




View more Hikma trades >>

Directors Deals for Hikma (HIK)
Trade DateActionNotifierPriceCurrencyAmountHolding
12-Jun-17Transfer From
Trade Notifier Information for Hikma Pharmaceuticals
Khalid Nabilsi held the position of CFO at Hikma Pharmaceuticals at the time of this trade.
 Khalid Nabilsi
012,842209700
30-May-17Transfer From
Trade Notifier Information for Hikma Pharmaceuticals
Said Darwazah held the position of Chairman and CEO at Hikma Pharmaceuticals at the time of this trade.
 Said Darwazah
052,16414956362
30-May-17Transfer From
Trade Notifier Information for Hikma Pharmaceuticals
Mazen Darwazah held the position of Executive Vice Chairman at Hikma Pharmaceuticals at the time of this trade.
 Mazen Darwazah
038,0883412058
View more Hikma directors dealings >>


Fantom
Posts: 184
Opinion:Strong Buy
Price:1,890.00
After hours trading
Mon 21:04
Interesting to see heavyweight buying after the close. The pull back following the recent surge has been kept in a tight range which bodes well for further gains.
enzo88
Posts: 61
Opinion:No Opinion
Price:1,946.00
HKMPF and HKMPY
6 Sep '18
Anyone know what the difference is of the two tickers? Both are Hikma.
HKMPF is up 2%
HKMPY is up 26% ($10).
Fantom
Posts: 184
Opinion:Strong Buy
Price:2,010.00
RE: 2000p
6 Sep '18
US stock up 26% overnight. Any news?
Costa77
Posts: 283
Opinion:No Opinion
Price:2,012.00
RE: 2000p
4 Sep '18
It is bad when you have bought in at 2100, so guess depends on your holding :-)
volcano
Posts: 4,143
Opinion:No Opinion
Price:2,006.00
RE: 2000p
4 Sep '18
don't be greedy , it is not bad from £9 to £20 in six months.
View more share chat for Hikma (HIK) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.